This article provides a summary of significant announcements and financial results from various Hong Kong-listed companies, covering strategic partnerships, clinical achievements, financial performance, and regulatory developments.
Key Corporate Announcements
ZHAOKE OPHTH-B (06622) has entered into a definitive agreement to acquire the global rights to NVK002, an atropine sulfate ophthalmic solution.
BRAINAURORA-B (06681) has secured second place in the Third Xiong'an Vertical Large Model Application Competition. Additionally, its latest clinical research findings have been published in an internationally authoritative academic journal.
Shenghong Technology (02476) has issued a clarification to address inaccurate negative rumors circulating online, noting that its AI PCB orders continue to show growth.
MINIEYE (02431) has established a long-term strategic partnership with DiDi's delivery service arm, DiDi Huoyun. The collaboration aims to jointly promote the commercial and large-scale implementation of unmanned last-mile delivery solutions in urban areas.
Hengrui Medicine (01276) announced that its HRS-7058 capsules have been included in the list of Breakthrough Therapy Designations.
Financial Performance Updates
CHINA RES LAND (01109) reported a 5.6% year-on-year increase in its total contracted sales value for the first half of the year, reaching approximately RMB 116.5 billion.
NCI (01336) anticipates its net profit attributable to owners for the first half of 2026 to be in the range of RMB 20.719 billion to RMB 23.678 billion, representing a year-on-year growth of 40% to 60%.
China Aluminum Corporation (02600) expects its net profit attributable to owners for the first half of the year to increase by 58% to 73% compared to the same period last year.
Longfor Group (00960) achieved a cumulative total contracted sales value of RMB 16.55 billion in the first six months.
Lingbao Gold (03330) issued a positive profit alert, forecasting an interim net profit of approximately RMB 950 million to RMB 1.05 billion, an increase of roughly 42% to 57%.
Huaqin Technology (03296) expects its interim net profit attributable to owners to be between RMB 2.9 billion and RMB 3.05 billion, marking a year-on-year growth of 53.5% to 61.5%.
Pharmaron (03759) forecasts its net profit attributable to owners for the first half of the year to increase by 4% to 10%.
Angang Steel (00347) issued a profit warning, anticipating a net loss attributable to owners of approximately RMB 2.047 billion for the first half, which represents an expansion of about 83.59% year-on-year.
Zentek Group (01300) reported first-half revenue of approximately RMB 1.7505 billion, a 41.7% increase year-on-year.
Dingtai High-Tech (01377) expects its net profit attributable to owners for the first half to be between RMB 640 million and RMB 700 million, signifying a substantial year-on-year growth of 300.62% to 338.18%.
Comments